Abstract
Hyperkalemia is a challenging comorbidity to manage in patients with heart failure and chronic kidney disease, particularly when administering renin-angiotensin-aldosterone system inhibitors. We encountered an 88-year-old woman with hypertensive heart failure and chronic kidney disease. A mineralocorticoid receptor antagonist was able to be safely administered despite persistent hyperkalemia when sodium zirconium cyclosilicate, a non-absorbed, non-polymer zirconium silicate compound that preferentially exchanges hydrogen and sodium for potassium and ammonium ions in the gastrointestinal tract, was concomitantly administered. Sodium zirconium cyclosilicate might be a promising therapeutic tool to use in order to administer mineralocorticoid receptor antagonist safely in patients with heart failure, chronic kidney disease, and hyperkalemia.
| Original language | English |
|---|---|
| Pages (from-to) | 2093-2095 |
| Number of pages | 3 |
| Journal | Internal Medicine |
| Volume | 60 |
| Issue number | 13 |
| DOIs | |
| State | Published - 2021 |
Keywords
- Heart failure
- Hemodynamics
- Potassium
ASJC Scopus subject areas
- Internal Medicine